34097-37-5

Usage

Uses

Used in Pharmaceutical Industry:
N,N'-1H-PURINE-2,6-DIYBIS ACETAMIDE is used as a potential drug candidate for targeting purine metabolism or related pathways. Its unique structure and interaction with biochemical processes make it a promising compound for the development of new therapeutic agents.
Proper handling and storage protocols should be followed to ensure the safety and efficacy of N,N'-1H-PURINE-2,6-DIYBIS ACETAMIDE in its intended applications.

Upstream product

• 93-97-0 benzoic acid anhydride 
• 1904-98-9 2,6-diaminopurine 
• 108-24-7 acetic anhydride 

Downstream Products

• 114753-52-5 9-(3-azido-2,3-dideoxy-β-D-erythro-pentofuranosyl)-2,6-diaminopurine 
• 121231-92-3 2,6-diamino-9-(3-azido-2,3-dideoxy-α-D-erythro-pentofuranosyl)purine 
• 89419-13-6 N-[2-Acetylamino-9-(2-benzyloxy-1-benzyloxymethyl-ethoxymethyl)-9H-purin-6-yl]-acetamide 
• 89419-18-1 6-Amino-9-(2-benzyloxy-1-benzyloxymethyl-ethoxymethyl)-3,9-dihydro-purin-2-one 
• 89419-14-7 9-(2-Benzyloxy-1-benzyloxymethyl-ethoxymethyl)-9H-purine-2,6-diamine 
• 89419-16-9 9-(2-Benzyloxy-1-benzyloxymethyl-ethoxymethyl)-2-fluoro-9H-purin-6-ylamine 
• 89419-15-8 2-(6-Amino-2-fluoro-purin-9-ylmethoxy)-3-benzyloxy-propan-1-ol 
• 82410-32-0 ganciclovir 
• 869355-04-4 N'-[9-((2R,3R,5S)-3-Hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl]-N,N-dimethyl-formamidine 
• 159217-68-2 N'-(9-{(2R,3R,5S)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-3-hydroxy-tetrahydro-furan-2-yl}-6-oxo-6,9-dihydro-1H-purin-2-yl)-N,N-dimethyl-formamidine 

Relevant academic research and scientific papers

Prolinamides of Aminouracils, Organocatalyst Modifiable by Complementary Modules

We report the synthesis and evaluation of prolinamide organocatalysts that incorporate aminouracils. The features of these catalysts are enhanced NH acidity of the amide because of the electron-withdrawing nature of the heterocycle, an additional hydrogen-bond donor at the α or β positions of this functional group (using 6-aminouracil or 5,6-diaminouracil respectively), and it can be recovered due to its low solubility and used again without decreasing the enantioselectivity. A unique feature of these systems is the self-assembly capability with complementary modules by Watson–Crick interactions. These supramolecular adducts behave differently from the catalyst alone, some of them have lower performance but others improve the selectivity of the product. Therefore, this approach avoids the synthesis of many catalysts.